Status:
COMPLETED
An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium
Lead Sponsor:
AstraZeneca
Conditions:
Gastric Ulcer
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study is being done to see if Nexium I.V. can reduce and control stomach acid in mechanically ventilated, critically ill patients in an Intensive Care Unit setting.
Eligibility Criteria
Inclusion
- Critically ill male or female subjects 18 years or older who have a baseline gastric aspirate pH less then or equal to 4
- Subjects admitted to an ICU requiring mechanically ventilated
- Subjects will have at least one additional stress ulcer risk factor
Exclusion
- Anticipated use of pre-pyloric enteral feeding after screening until the end of study
- Physician estimated survival of less then 96 hours
- Anticipation of major surgery within 96 hours of study enrollment
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2006
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00428701
Start Date
October 1 2006
End Date
November 1 2006
Last Update
January 24 2011
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Research SIte
Newark, Delaware, United States
2
Research Site
Shreveport, Louisiana, United States
3
Research Site
Hershey, Pennsylvania, United States
4
Research Site
Memphis, Tennessee, United States